This may have implications not only on that the resistin-ADSC-CXCL5 pathway as a therapeutic target, but on the re-evaluation of factors that may affect ADSC activities in the tumor microenvironment, such as neoadjuvant and adjuvant therapies, and post-surgical autologous fat grafting in breast cancer patients47. This evidence concerns the gene RETN and breast cancer.